

## Press Release

### SYGNIS AG reports results for the first quarter 2016

- **Promotion activities enhanced**
- **Further expansion of direct sales capacities**
- **Revenues increased year-on-year by 20%**
- **Net loss reduced year-on-year by 7%**
- **Company plans to acquire profitable proteomics player Expedeon Holdings Ltd. (after period-end)**

**Madrid, Spain and Heidelberg, Germany, 12 May 2016** – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced its financial results for the first quarter of 2016, ended 31 March 2016.

#### Financials first quarter 2016:

In the first quarter of 2016, revenues were up by 20% to €91 thousand, after €76 thousand in the previous year. This increase is primarily due to higher kit sales. These were up 50% compared to the previous year, and thus able to balance lower revenues from Caco-2 licensing rights in the US.

Operating loss improved by 7% to €673 thousand (Q1 2015: €721 thousand). Operating expenses included sales, general & administrative costs of €456 thousand as well as research & development costs of €318 thousand. The decrease of operating costs is mainly due to lower administrative expenses as a result of the optimization efforts regarding the cost structure in 2015.

As of 31 March 2016, cash and cash equivalents amounted to €3.4 million (31 December 2015: €4.6 million). Total short term assets were €816 thousand (December 31, 2015: €883 thousand). Cash outflow from operating activities amounted to –€1,062 thousand (Q1 2015: –€1,176 thousand).

#### Operational Highlights:

In the first quarter 2016 the business focus was on advancing the commercialization of SYGNIS' own six kits that were successfully launched in 2015. Furthermore, the Company concentrated on the development of additional innovative and highly competitive kits for core applications to be launched during 2016, most importantly a cell-free DNA amplification kit, targeting the oncology market, and a liquid biopsy kit. During 2015 and continued in the first quarter of 2016, SYGNIS made big progress in expanding its direct sales capacities and started to promote its own products. Moreover, the Company is in advanced discussions for outlicensing products under non-exclusive conditions, in order to have agreements in place.

Enhanced marketing activities: In the first quarter 2016, SYGNIS participated and presented its products at the Festival of Genomics in London, UK, in January. This congress is an assembly of leaders in the sector who discussed the future of medicine in the European genetics community and the participants shared their thoughts on the knowledge, skills and experience in using genomic medicine. In addition, SYGNIS boosted its marketing activities presenting at two renowned scientific conferences in Europe and the U.S. In March 2016,

the Company presented its revolutionary novel multiple displacement amplification (MDA) technology TruePrime™ at the 23rd Molecular Medicine Tri Conference (Molecular Med TRI-CON) in San Francisco, CA, USA, and at the 10th International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment (ISMRC) in Hamburg, Germany.

Planned acquisition of Expedeon Holdings Ltd. (after period-end): On 9 May 2016, SYGNIS resolved, with the approval of the Supervisory Board, to acquire Expedeon Holdings Ltd., a privately held UK proteomics company with sales offices in the US, UK and Singapore. Expedeon develops, manufactures and commercializes proteomics reagents and tools, marketed worldwide by Expedeon`s direct sales force and via distributors. The acquisition shall provide a well-established direct sales force in the US and Europe and broaden the Company`s product portfolio. For this transaction, SYGNIS plans a capital increase by way of a rights offering of up to 20.5 million shares. The Company intends to acquire Expedeon by issuing approximately 80% of the new shares against contributions in kind (Expedeon shares). Expected proceeds from the capital increase of up to €5 million will be used for transaction-related expenses, including €1.7 million cash payments to Expedeon shareholders, one-off integration costs and financing working capital. The transaction will be subject to the approval by the Annual General Meeting on 20 June 2016. The subscription price for the allocation in cash will be defined subsequently.

“In the first quarter 2016 we focused on advancing commercialization as well as on expanding our direct sales and marketing activities. We will launch three more kits in the course of 2016, especially the liquid biopsy kit will be very promising. Furthermore, in Q1 we were successful in finding an attractive acquisition target: the planned acquisition of Expedeon Holdings Ltd. was just published on 9 May 2016”, **Pilar de la Huerta, CEO and CFO of SYGNIS commented.** “The company perfectly fits our business model. As Expedeon has a strong sales force and already generates profitable sales, the combination of the two companies will match our innovative products with Expedeon`s experienced sales force covering all significant markets. With approximately 30% of the revenues generated from the US, Expedeon has a particularly strong foothold in this important market. Following the successful acquisition, each company will benefit from the other`s experience and established processes. I am convinced that we will become a leading life sciences reagents and tools company, covering both the genomics and proteomics markets.”

**Figures Q1 2016 and comparative figures in accordance with IFRS**

[Numbers in € thousand]	Q1/2016	Q1/2015
Revenues	91	76
Operating expenses	764	797
EBIT	-673	-721
Net results for the period	-677	-735
Operating Cash Flow	-1,062	-1,175
	<b>31 March 2016</b>	<b>31 March 2015</b>
Liquidity at period-end	3,369	2,515
Equity	9,718	7,570
Equity ratio	75.7%	66.3%
Long-term financial liabilities	1,913	2,912

The interim report for the first quarter, ended 31 March 2016, is available for download from the Company's webpage at [www.sygnis.com](http://www.sygnis.com).

**For further information please contact:**

**SYGNIS AG**

Pilar de la Huerta

CEO/CFO

Phone: +34 91 192 36 50

Email: [pdelahuerta@sygnis.com](mailto:pdelahuerta@sygnis.com)

**MC Services AG**

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 30

Email: [raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

**About SYGNIS AG: [www.sygnis.com](http://www.sygnis.com)**

SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###